Ipsen announced that in collaboration with the Food and Drug Administration (FDA), it is releasing a third batch of Increlex (mecasermin [rDNA origin]), since the initial resumption of product supply in May 2014.
Interruption in Increlex supply occurred in mid-June 2013 due to manufacturing issues. Since then, the first batch of Increlex was made available for distribution in June of 2014.
Increlex is a recombinant human insulin-like growth factor-1 (rhIGF-1) indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (IGFD), or in those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
For more information call (866) 837-2422 or visit Ipsen.com.